{"id":"conventional-low-dose-thromboprophylaxis","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Heparin-induced thrombocytopenia (HIT)"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL2108580","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This approach uses standard anticoagulant agents (such as unfractionated heparin, low-molecular-weight heparin, or warfarin) at lower doses than those used for therapeutic anticoagulation. The reduced dosing is designed to prevent thrombotic events in high-risk patients while minimizing bleeding complications. It is commonly employed in surgical, orthopedic, and medical settings to reduce venous thromboembolism risk.","oneSentence":"Conventional low-dose thromboprophylaxis prevents blood clot formation by inhibiting coagulation cascade factors, typically using anticoagulants at reduced doses for prevention rather than treatment.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:07:36.841Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Thromboprophylaxis in surgical patients"},{"name":"Thromboprophylaxis in orthopedic surgery patients"},{"name":"Thromboprophylaxis in medical patients at risk for venous thromboembolism"}]},"trialDetails":[{"nctId":"NCT07411768","phase":"NA","title":"Low-dose Colchicine for Thromboprophylaxis After Transcatheter Aortic Valve Replacement","status":"NOT_YET_RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2026-03","conditions":"Transcatheter Aortic Valve Replacement, Transcatheter Heart Valve Thrombosis, Anti-inflammatory Therapy","enrollment":116},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Conventional low dose thromboprophylaxis","genericName":"Conventional low dose thromboprophylaxis","companyName":"UMC Utrecht","companyId":"umc-utrecht","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Conventional low-dose thromboprophylaxis prevents blood clot formation by inhibiting coagulation cascade factors, typically using anticoagulants at reduced doses for prevention rather than treatment. Used for Thromboprophylaxis in surgical patients, Thromboprophylaxis in orthopedic surgery patients, Thromboprophylaxis in medical patients at risk for venous thromboembolism.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}